In the present study, S-1 therapy plus apatinib outperformed the single therapy of S-1 therapy in mitigating the levels of IFN-γ, TNF-α, IL-4, and IL-10, indicating that apatinib plus S-1 can effectively improve the degree of Th1 and Th2 drift in the patient's body, which consequently enhances the cytokine levels in patients with advanced gastric cancer [21]. Here, IL10 is linked to gastric cancer.